Its incredible to contemplate that Neuren could go-it-alone in taking NNZ-2591 through to approval, funded by milestone payments from Trofinetide. I would assume that the opportunity to gain approval off a successful Phase 2 trial would be enhanced by Orphan Drug approval. Trofinetide will also light up the clinical pathway for its sibling.
- Forums
- ASX - By Stock
- NEU
- Ann: Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.00%
!
$12.85

Ann: Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA, page-7
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.85 |
Change
0.000(0.00%) |
Mkt cap ! $1.598B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16 | $14.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.07 | 152 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16 | 14.070 |
6 | 302 | 13.630 |
1 | 6 | 13.500 |
8 | 750 | 13.490 |
1 | 1 | 13.230 |
Price($) | Vol. | No. |
---|---|---|
12.070 | 68 | 3 |
12.210 | 87 | 1 |
12.220 | 79 | 2 |
12.470 | 38 | 1 |
12.510 | 639 | 1 |
Last trade - 09.59am 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
RC1
REDCASTLE RESOURCES LIMITED
Ronald Miller, Non-Executive Director
Ronald Miller
Non-Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online